Chemotherapy-induced Nausea and Vomiting Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy.

The global market for Chemotherapy-induced Nausea and Vomiting Drugs was estimated to be worth US$ 1689.4 million in 2023 and is forecast to a readjusted size of US$ 2358.3 million by 2030 with a CAGR of 4.4% during the forecast period 2024-2030

Chemotherapy-induced Nausea and Vomiting Drugs Market Size

M= millions and B=billions

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Chemotherapy-induced Nausea and Vomiting Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Chemotherapy-induced Nausea and Vomiting Drugs by region & country, by Type, and by Application.

The Chemotherapy-induced Nausea and Vomiting Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy-induced Nausea and Vomiting Drugs.

Market Segmentation

• Report Metric

• Details

• Report Title

• Chemotherapy-induced Nausea and Vomiting Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

• Forecasted Market Size in 2030

• US$ 2358.3 million

• CAGR(2024-2030)

• 4.4%

• Market Size Available for Years

• 2019-2030

• Global Chemotherapy-induced Nausea and Vomiting Drugs Companies Covered

• Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Heron Therapeutics, Roche, Mylan, Tesaro

• Global Chemotherapy-induced Nausea and Vomiting Drugs Market, by Region

• North America (U.S., Canada, Mexico)

  Europe (Germany, France, UK, Italy, etc.)

  Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

  South America (Brazil, etc.)

  Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

• Global Chemotherapy-induced Nausea and Vomiting Drugs Market, Segment by Type

• 5-HT3 Inhibitors

  NK1 Inhibitors

  Other

• Global Chemotherapy-induced Nausea and Vomiting Drugs Market, Segment by Application

• Highly Emetogenic Chemotherapy

  Moderately Emetogenic Chemotherapy

  Low Emetogenic Chemotherapy

  Other

• Forecast Units

• USD million in value

• Report Coverage

• Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Chemotherapy-induced Nausea and Vomiting Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Chemotherapy-induced Nausea and Vomiting Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Chemotherapy-induced Nausea and Vomiting Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

 1 Market Overview
    1.1 Chemotherapy-induced Nausea and Vomiting Drugs Product Introduction
    1.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size Forecast
        1.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2019-2030)
        1.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume (2019-2030)
        1.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Price (2019-2030)
    1.3 Chemotherapy-induced Nausea and Vomiting Drugs Market Trends & Drivers
        1.3.1 Chemotherapy-induced Nausea and Vomiting Drugs Industry Trends
        1.3.2 Chemotherapy-induced Nausea and Vomiting Drugs Market Drivers & Opportunity
        1.3.3 Chemotherapy-induced Nausea and Vomiting Drugs Market Challenges
        1.3.4 Chemotherapy-induced Nausea and Vomiting Drugs Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Players Revenue Ranking (2023)
    2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Company (2019-2024)
    2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Players Sales Volume Ranking (2023)
    2.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Company Players (2019-2024)
    2.5 Global Chemotherapy-induced Nausea and Vomiting Drugs Average Price by Company (2019-2024)
    2.6 Key Manufacturers Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers Chemotherapy-induced Nausea and Vomiting Drugs Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of Chemotherapy-induced Nausea and Vomiting Drugs
    2.9 Chemotherapy-induced Nausea and Vomiting Drugs Market Competitive Analysis
        2.9.1 Chemotherapy-induced Nausea and Vomiting Drugs Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by Chemotherapy-induced Nausea and Vomiting Drugs Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy-induced Nausea and Vomiting Drugs as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 5-HT3 Inhibitors
        3.1.2 NK1 Inhibitors
        3.1.3 Other
    3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type
        3.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, by Type (2019-2030)
        3.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, by Type (%) (2019-2030)
    3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type
        3.3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume, by Type (2019-2030)
        3.3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume, by Type (%) (2019-2030)
    3.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Highly Emetogenic Chemotherapy
        4.1.2 Moderately Emetogenic Chemotherapy
        4.1.3 Low Emetogenic Chemotherapy
        4.1.4 Other
    4.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application
        4.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, by Application (2019-2030)
        4.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, by Application (%) (2019-2030)
    4.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application
        4.3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume, by Application (2019-2030)
        4.3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume, by Application (%) (2019-2030)
    4.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region
        5.1.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (2019-2024)
        5.1.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (2025-2030)
        5.1.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (%), (2019-2030)
    5.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Region
        5.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Region (2019-2024)
        5.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Region (2025-2030)
        5.2.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Region (%), (2019-2030)
    5.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        5.4.2 North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        5.5.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        5.6.2 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        5.7.2 South America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        5.8.2 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Value
        6.2.1 Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        6.2.2 Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        6.3.2 United States Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        6.4.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        6.5.2 China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        6.6.2 Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        6.7.2 South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        6.8.2 Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019-2030
        6.9.2 India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Merck
        7.1.1 Merck Company Information
        7.1.2 Merck Introduction and Business Overview
        7.1.3 Merck Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Merck Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
        7.1.5 Merck Recent Development
    7.2 Eisai
        7.2.1 Eisai Company Information
        7.2.2 Eisai Introduction and Business Overview
        7.2.3 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
        7.2.5 Eisai Recent Development
    7.3 Mundipharma
        7.3.1 Mundipharma Company Information
        7.3.2 Mundipharma Introduction and Business Overview
        7.3.3 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
        7.3.5 Mundipharma Recent Development
    7.4 Qilu Pharma
        7.4.1 Qilu Pharma Company Information
        7.4.2 Qilu Pharma Introduction and Business Overview
        7.4.3 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
        7.4.5 Qilu Pharma Recent Development
    7.5 Teva
        7.5.1 Teva Company Information
        7.5.2 Teva Introduction and Business Overview
        7.5.3 Teva Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Teva Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
        7.5.5 Teva Recent Development
    7.6 Novartis
        7.6.1 Novartis Company Information
        7.6.2 Novartis Introduction and Business Overview
        7.6.3 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.6.4 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
        7.6.5 Novartis Recent Development
    7.7 Heron Therapeutics
        7.7.1 Heron Therapeutics Company Information
        7.7.2 Heron Therapeutics Introduction and Business Overview
        7.7.3 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.7.4 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
        7.7.5 Heron Therapeutics Recent Development
    7.8 Roche
        7.8.1 Roche Company Information
        7.8.2 Roche Introduction and Business Overview
        7.8.3 Roche Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.8.4 Roche Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
        7.8.5 Roche Recent Development
    7.9 Mylan
        7.9.1 Mylan Company Information
        7.9.2 Mylan Introduction and Business Overview
        7.9.3 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.9.4 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
        7.9.5 Mylan Recent Development
    7.10 Tesaro
        7.10.1 Tesaro Company Information
        7.10.2 Tesaro Introduction and Business Overview
        7.10.3 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
        7.10.4 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
        7.10.5 Tesaro Recent Development

 8 Industry Chain Analysis
    8.1 Chemotherapy-induced Nausea and Vomiting Drugs Industrial Chain
    8.2 Chemotherapy-induced Nausea and Vomiting Drugs Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Chemotherapy-induced Nausea and Vomiting Drugs Sales Model
        8.5.2 Sales Channel
        8.5.3 Chemotherapy-induced Nausea and Vomiting Drugs Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Chemotherapy-induced Nausea and Vomiting Drugs Market Trends
    Table 2. Chemotherapy-induced Nausea and Vomiting Drugs Market Drivers & Opportunity
    Table 3. Chemotherapy-induced Nausea and Vomiting Drugs Market Challenges
    Table 4. Chemotherapy-induced Nausea and Vomiting Drugs Market Restraints
    Table 5. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Chemotherapy-induced Nausea and Vomiting Drugs Price by Company (2019-2024) & (USD/Unit)
    Table 10. Key Manufacturers Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Chemotherapy-induced Nausea and Vomiting Drugs Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Chemotherapy-induced Nausea and Vomiting Drugs
    Table 13. Global Chemotherapy-induced Nausea and Vomiting Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy-induced Nausea and Vomiting Drugs as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Chemotherapy-induced Nausea and Vomiting Drugs Price by Type (2019-2024) & (USD/Unit)
    Table 27. Global Chemotherapy-induced Nausea and Vomiting Drugs Price by Type (2025-2030) & (USD/Unit)
    Table 28. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Chemotherapy-induced Nausea and Vomiting Drugs Price by Application (2019-2024) & (USD/Unit)
    Table 39. Global Chemotherapy-induced Nausea and Vomiting Drugs Price by Application (2025-2030) & (USD/Unit)
    Table 40. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (2019-2024) & (%)
    Table 44. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (2025-2030) & (%)
    Table 45. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Chemotherapy-induced Nausea and Vomiting Drugs Average Price by Region (2019-2024) & (USD/Unit)
    Table 51. Global Chemotherapy-induced Nausea and Vomiting Drugs Average Price by Region (2025-2030) & (USD/Unit)
    Table 52. Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume, (2025-2030) & (K Units)
    Table 57. Merck Company Information
    Table 58. Merck Introduction and Business Overview
    Table 59. Merck Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 60. Merck Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
    Table 61. Merck Recent Development
    Table 62. Eisai Company Information
    Table 63. Eisai Introduction and Business Overview
    Table 64. Eisai Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 65. Eisai Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
    Table 66. Eisai Recent Development
    Table 67. Mundipharma Company Information
    Table 68. Mundipharma Introduction and Business Overview
    Table 69. Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 70. Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
    Table 71. Mundipharma Recent Development
    Table 72. Qilu Pharma Company Information
    Table 73. Qilu Pharma Introduction and Business Overview
    Table 74. Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 75. Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
    Table 76. Qilu Pharma Recent Development
    Table 77. Teva Company Information
    Table 78. Teva Introduction and Business Overview
    Table 79. Teva Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 80. Teva Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
    Table 81. Teva Recent Development
    Table 82. Novartis Company Information
    Table 83. Novartis Introduction and Business Overview
    Table 84. Novartis Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 85. Novartis Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
    Table 86. Novartis Recent Development
    Table 87. Heron Therapeutics Company Information
    Table 88. Heron Therapeutics Introduction and Business Overview
    Table 89. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 90. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
    Table 91. Heron Therapeutics Recent Development
    Table 92. Roche Company Information
    Table 93. Roche Introduction and Business Overview
    Table 94. Roche Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 95. Roche Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
    Table 96. Roche Recent Development
    Table 97. Mylan Company Information
    Table 98. Mylan Introduction and Business Overview
    Table 99. Mylan Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 100. Mylan Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
    Table 101. Mylan Recent Development
    Table 102. Tesaro Company Information
    Table 103. Tesaro Introduction and Business Overview
    Table 104. Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 105. Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Product Offerings
    Table 106. Tesaro Recent Development
    Table 107. Key Raw Materials Lists
    Table 108. Raw Materials Key Suppliers Lists
    Table 109. Chemotherapy-induced Nausea and Vomiting Drugs Downstream Customers
    Table 110. Chemotherapy-induced Nausea and Vomiting Drugs Distributors List
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Chemotherapy-induced Nausea and Vomiting Drugs Product Picture
    Figure 2. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Price (2019-2030) & (USD/Unit)
    Figure 6. Chemotherapy-induced Nausea and Vomiting Drugs Report Years Considered
    Figure 7. Global Chemotherapy-induced Nausea and Vomiting Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Chemotherapy-induced Nausea and Vomiting Drugs Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Chemotherapy-induced Nausea and Vomiting Drugs Revenue in 2023
    Figure 10. Chemotherapy-induced Nausea and Vomiting Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. 5-HT3 Inhibitors Picture
    Figure 12. NK1 Inhibitors Picture
    Figure 13. Other Picture
    Figure 14. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 16. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 17. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Market Share by Type, 2023 & 2030
    Figure 18. Global Chemotherapy-induced Nausea and Vomiting Drugs Price by Type (2019-2030) & (USD/Unit)
    Figure 19. Product Picture of Highly Emetogenic Chemotherapy
    Figure 20. Product Picture of Moderately Emetogenic Chemotherapy
    Figure 21. Product Picture of Low Emetogenic Chemotherapy
    Figure 22. Product Picture of Other
    Figure 23. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 24. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 25. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 26. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Market Share by Application, 2023 & 2030
    Figure 27. Global Chemotherapy-induced Nausea and Vomiting Drugs Price by Application (2019-2030) & (USD/Unit)
    Figure 28. North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 29. North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 30. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 31. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 32. Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 33. Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 34. South America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 35. South America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 36. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 37. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 38. Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (%), (2019-2030)
    Figure 39. Key Countries/Regions Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume (%), (2019-2030)
    Figure 40. United States Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 41. United States Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 42. United States Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 43. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 45. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 46. China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 47. China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 48. China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 49. Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 50. Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 51. Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 52. South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 53. South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 54. South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 55. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 56. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 57. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 58. India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 59. India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 60. India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 61. Chemotherapy-induced Nausea and Vomiting Drugs Industrial Chain
    Figure 62. Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Cost Structure
    Figure 63. Channels of Distribution (Direct Sales, and Distribution)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed

Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy.

The global market for Chemotherapy-induced Nausea and Vomiting Drugs was estimated to be worth US$ 1689.4 million in 2023 and is forecast to a readjusted size of US$ 2358.3 million by 2030 with a CAGR of 4.4% during the forecast period 2024-2030

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Chemotherapy-induced Nausea and Vomiting Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Chemotherapy-induced Nausea and Vomiting Drugs by region & country, by Type, and by Application.

The Chemotherapy-induced Nausea and Vomiting Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy-induced Nausea and Vomiting Drugs.

Market Segmentation

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Chemotherapy-induced Nausea and Vomiting Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Chemotherapy-induced Nausea and Vomiting Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Chemotherapy-induced Nausea and Vomiting Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.